MX2010003110A - Composiciones de polipeptido de elemento nuclear intercalado largo y metodos de uso de las mismas. - Google Patents

Composiciones de polipeptido de elemento nuclear intercalado largo y metodos de uso de las mismas.

Info

Publication number
MX2010003110A
MX2010003110A MX2010003110A MX2010003110A MX2010003110A MX 2010003110 A MX2010003110 A MX 2010003110A MX 2010003110 A MX2010003110 A MX 2010003110A MX 2010003110 A MX2010003110 A MX 2010003110A MX 2010003110 A MX2010003110 A MX 2010003110A
Authority
MX
Mexico
Prior art keywords
line
compositions
present
methods
intercaled
Prior art date
Application number
MX2010003110A
Other languages
English (en)
Spanish (es)
Inventor
Mario Ostrowski
R Bradley Jones
Douglas Nixon
Keith Garrison
Duncan Meiklejohn
Ashish Agrawal
Frederick M Hecht
Original Assignee
David Gladstone Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by David Gladstone Inst filed Critical David Gladstone Inst
Publication of MX2010003110A publication Critical patent/MX2010003110A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
MX2010003110A 2007-09-20 2008-09-19 Composiciones de polipeptido de elemento nuclear intercalado largo y metodos de uso de las mismas. MX2010003110A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97399307P 2007-09-20 2007-09-20
PCT/US2008/010883 WO2009038756A2 (en) 2007-09-20 2008-09-19 Long interspersed nuclear element polypeptide compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2010003110A true MX2010003110A (es) 2010-05-19

Family

ID=40468692

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003110A MX2010003110A (es) 2007-09-20 2008-09-19 Composiciones de polipeptido de elemento nuclear intercalado largo y metodos de uso de las mismas.

Country Status (11)

Country Link
US (1) US20110046042A1 (enExample)
EP (1) EP2200637A4 (enExample)
JP (1) JP2010539901A (enExample)
KR (1) KR20100075483A (enExample)
CN (1) CN101969987A (enExample)
AU (1) AU2008301888A1 (enExample)
BR (1) BRPI0817209A2 (enExample)
CA (1) CA2700115A1 (enExample)
MX (1) MX2010003110A (enExample)
RU (1) RU2010115088A (enExample)
WO (1) WO2009038756A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CA2638823A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
US8647640B2 (en) 2009-06-24 2014-02-11 Richard E. COWART Vaccine compositions and methods of use to protect against infectious disease
US20140031250A1 (en) * 2010-10-07 2014-01-30 David Tsai Ting Biomarkers of Cancer
WO2014004945A1 (en) * 2012-06-28 2014-01-03 University Of Louisville Research Foundation, Inc. Use of protein line-1 orf-1 as a biomarker for cancer
ES2723885T3 (es) 2012-07-19 2019-09-03 Daiichi Sankyo Co Ltd Anticuerpos anti-Siglec-15
EP3760208B1 (en) 2014-06-25 2024-05-29 The General Hospital Corporation Targeting human satellite ii (hsatii)
WO2016159377A1 (ja) * 2015-04-03 2016-10-06 国立大学法人京都大学 がんの治療薬のスクリーニング方法
GB201507030D0 (en) * 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
CA3154827A1 (en) * 2019-10-16 2021-04-22 Valerio Orlando Methods for modulating human l1 retrotransposons rna and compositions for use therein
EP4081309A4 (en) * 2019-12-26 2024-01-17 The Johns Hopkins University ENHANCED LINE-1 ENCODED ORF2P EXPRESSION FOR CANCER THERAPEUTIC AGENTS
JP7569054B2 (ja) 2020-06-02 2024-10-17 学校法人東京女子医科大学 Ｓ１００ａ８阻害ペプチドとこれを含む疾患治療薬

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5280108A (en) * 1991-09-27 1994-01-18 United States Of America Antibodies to p40
ES2309992T3 (es) * 1995-10-20 2008-12-16 University Of Nebraska Board Of Regents Composiciones y procedimientos para incrementar las respuestas inmunes mediadas por celulas presentadoras de antigeno.
CN1315379A (zh) * 2000-03-27 2001-10-03 上海博德基因开发有限公司 一种新的多肽——人L1因子p40蛋白12和编码这种多肽的多核苷酸
CN1315332A (zh) * 2000-03-27 2001-10-03 上海博德基因开发有限公司 一种新的多肽——l1－12和编码这种多肽的多核苷酸
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US7700359B2 (en) * 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
CN1339478A (zh) * 2000-08-21 2002-03-13 上海博德基因开发有限公司 一种新的多肽——人l1因子orf2相关蛋白10.78和编码这种多肽的多核苷酸
CN1339450A (zh) * 2000-08-21 2002-03-13 上海博德基因开发有限公司 一种新的多肽——转座元蛋白14.41和编码这种多肽的多核苷酸
CN1343776A (zh) * 2000-09-19 2002-04-10 上海博德基因开发有限公司 一种新的多肽——dna聚合酶9.02和编码这种多肽的多核苷酸
CN1352094A (zh) * 2000-11-06 2002-06-05 上海博德基因开发有限公司 一种新的多肽——人l1元件类蛋白19.80和编码这种多肽的多核苷酸
CN1425684A (zh) * 2001-12-19 2003-06-25 复旦大学 一种多肽——人反转录转座40蛋白－12.76和编码这种多肽的多核苷酸
WO2004039952A2 (en) * 2002-10-25 2004-05-13 Five Prime Therapeutics, Inc. Methods of use for novel human polypeptides encoded by polynucleotides
EP1609107A4 (en) * 2003-03-28 2006-08-30 Idm Pharma Inc METHOD FOR IDENTIFYING OPTIMAL PEPTIDE PITOPARIANTS
WO2005049789A2 (en) * 2003-05-28 2005-06-02 The Johns Hopkins University Synthetic mammalian retrotransposon gene

Also Published As

Publication number Publication date
WO2009038756A3 (en) 2009-05-14
EP2200637A4 (en) 2011-10-19
CN101969987A (zh) 2011-02-09
CA2700115A1 (en) 2009-03-26
US20110046042A1 (en) 2011-02-24
BRPI0817209A2 (pt) 2015-03-10
WO2009038756A2 (en) 2009-03-26
RU2010115088A (ru) 2011-10-27
JP2010539901A (ja) 2010-12-24
EP2200637A2 (en) 2010-06-30
KR20100075483A (ko) 2010-07-02
AU2008301888A1 (en) 2009-03-26

Similar Documents

Publication Publication Date Title
MX2010003110A (es) Composiciones de polipeptido de elemento nuclear intercalado largo y metodos de uso de las mismas.
AR134186A2 (es) Un anticuerpo anti-csf-1r, un proceso para producirlo, una composición farmacéutica que lo comprende, una secuencia de adn aislado, un vector de expresión o clonación y una célula hospedadora
MX2009000659A (es) Composiciones de polipeptidos de retrovirus endogeno humano y metodo para su uso.
CO2017010831A2 (es) Adenovirus oncolítico que codifica una proteína b7
MX362981B (es) Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido.
ES2662801T3 (es) Vacunas atenuadas contra Streptoccocus suis y procedimientos de fabricación y uso de las mismas
MX354555B (es) Polipeptidos de la hormona de crecimiento y metodos de preparacion y su uso.
MX389093B (es) Composiciones y metodos para la glicosilacion de proteinas.
UY37635A (es) Anticuerpos anti phf-tau y sus usos
CL2017002199A1 (es) Vectores retrovirales a lentivirales
BRPI0510475B8 (pt) adenovírus quimérico recombinante, uso do mesmo no tratamento de câncer e métodos de inibição de crescimento de uma célula de câncer, de fornecimento de uma proteína terapêutica a uma célula e para o isolamento do adenovírus
CO2018012513A2 (es) Anticuerpos
UY31533A1 (es) Moleculas de enlace al receptor humano ox40
BR112012015740A2 (pt) anticorpos de anti-flt3 e metodos de uso dos mesmos
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
AR079114A1 (es) Proteinas de enlace de antigenos anti-orai1 y usos de las mismas
AR072022A1 (es) Genes involucrados en biosintesis de flavonoides en plantas
MX2015002994A (es) Peptidos de inhibidores obtenidos del receptor desencadenante expresado en celulas mieloides de tipo 1 (trem-1) y transcrito similar a trem 1 (tlt-1) y usos de los mismos.
CL2017003097A1 (es) Composiciones y métodos para el tratamiento de la enfermedad celiaca
AR075933A1 (es) Composiciones polipeptidas y de inmunizacion conteniendo polipeptidos positivos gram y metodos de uso
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
EP2528937A4 (en) MODIFIED MELK-PEPTIDES AND VACCINES CONTAINING THEREOF
CY1125328T1 (el) Ανασυνδυασμενο εμβολιο ιου λευχαιμιας αιλουροειδων περιεχοντας βελτιστοποιημενο γονιδιο φακελου ιου λευχαιμιας αιλουροειδων
AR084095A1 (es) Peptidos tomm34 y vacunas que los incluyen
SG10201408245WA (en) Tmem22 peptides and vaccines including the same

Legal Events

Date Code Title Description
FA Abandonment or withdrawal